January 17, 2014
Mitsubishi Tanabe Pharma Corporation (MTPC) announced on January 16 that it has filed an application for the additional indication of chronic hepatitis C genotype 2 for its chronic hepatitis C treatment Telavic 250 mg Tablets (telaprevir). According to the company,...read more